Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Fall/winter depression and its therapy]

A Neumeister1, T Kapitany, N Rieder

  • 1Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien.

Wiener Klinische Wochenschrift
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

ESMO gastrointestinal oncology·2026
Same author

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

ESMO gastrointestinal oncology·2026
Same author

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Seasonal Affective Disorder (SAD) is a mood disorder linked to fall/winter, improving in spring/summer. Light therapy and antidepressants are effective treatments for this condition.

Area of Science:

  • Psychiatry
  • Chronobiology
  • Clinical Psychology

Context:

  • Seasonal changes in human behavior have been observed for centuries.
  • Systematic research on a specific syndrome linked to seasons began in 1980.
  • Seasonal Affective Disorder (SAD) is a recognized clinical condition.

Purpose:

  • To describe and characterize the psychopathological and clinical features of Seasonal Affective Disorder (SAD).
  • To review the established and emerging treatments for SAD.
  • To highlight the efficacy of specific therapeutic interventions for SAD.

Summary:

  • Seasonal Affective Disorder (SAD) is characterized by a distinct pattern of symptoms including depressed mood, reduced energy, hypersomnia, increased appetite, weight gain, and carbohydrate craving.

Related Experiment Videos

  • The disorder is specifically linked to the fall/winter seasons, with symptom remission occurring in spring/summer.
  • Effective treatments for fall/winter SAD include bright light therapy and selective serotonin reuptake inhibitors (SSRIs).

    • Impact:

    • Provides a clear definition and understanding of SAD symptomatology and seasonal patterns.
    • Confirms the therapeutic efficacy of light therapy for SAD.
    • Supports the use of SSRIs as a successful treatment modality for SAD.
    • Informs clinical practice and patient care for individuals experiencing seasonal mood changes.